Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Sees Significant Increase in Short Interest

Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) was the target of a large growth in short interest in the month of July. As of July 15th, there was short interest totaling 5,179 shares, a growth of 154.7% from the June 30th total of 2,033 shares. Based on an average daily volume of 869 shares, the days-to-cover ratio is currently 6.0 days.

Algernon Pharmaceuticals Trading Up 2.3%

AGNPF stock opened at $0.30 on Tuesday. Algernon Pharmaceuticals has a fifty-two week low of $0.23 and a fifty-two week high of $0.64. The business’s fifty day moving average price is $0.31 and its two-hundred day moving average price is $0.16.

About Algernon Pharmaceuticals

Algernon Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel, small-molecule therapeutics. The company’s primary strategy centers on repurposing known compounds with established safety profiles to address unmet medical needs, particularly in the realms of pulmonary fibrosis, acute lung injury and central nervous system (CNS) disorders. By leveraging existing pharmacology data, Algernon aims to accelerate its development timelines while managing costs and risks typically associated with early-stage drug discovery.

The lead asset in Algernon’s pipeline is NP-120 (ifenprodil), an orally available small molecule being investigated for idiopathic pulmonary fibrosis (IPF).